- Home
- ZNTL vs PSTX Comparison
ZNTL vs PSTX Comparison
Compare ZNTL & PSTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- PSTX
- Stock Information
- Founded
- ZNTL 2014
- PSTX 2014
- Country
- ZNTL United States
- PSTX United States
- Employees
- ZNTL N/A
- PSTX N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- PSTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZNTL Health Care
- PSTX Health Care
- Exchange
- ZNTL Nasdaq
- PSTX Nasdaq
- Market Cap
- ZNTL 238.2M
- PSTX 249.1M
- IPO Year
- ZNTL 2020
- PSTX 2020
- Fundamental
- Price
- ZNTL $3.12
- PSTX $2.50
- Analyst Decision
- ZNTL Buy
- PSTX Strong Buy
- Analyst Count
- ZNTL 7
- PSTX 2
- Target Price
- ZNTL $10.86
- PSTX $15.00
- AVG Volume (30 Days)
- ZNTL 1.2M
- PSTX 539.2K
- Earning Date
- ZNTL 11-04-2024
- PSTX 11-07-2024
- Dividend Yield
- ZNTL N/A
- PSTX N/A
- EPS Growth
- ZNTL N/A
- PSTX N/A
- EPS
- ZNTL N/A
- PSTX N/A
- Revenue
- ZNTL $40,560,000.00
- PSTX $88,462,000.00
- Revenue This Year
- ZNTL N/A
- PSTX $36.53
- Revenue Next Year
- ZNTL N/A
- PSTX N/A
- P/E Ratio
- ZNTL N/A
- PSTX N/A
- Revenue Growth
- ZNTL N/A
- PSTX N/A
- 52 Week Low
- ZNTL $2.83
- PSTX $1.83
- 52 Week High
- ZNTL $18.24
- PSTX $4.27
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- PSTX 38.80
- Support Level
- ZNTL $2.92
- PSTX $2.41
- Resistance Level
- ZNTL $3.23
- PSTX $2.61
- Average True Range (ATR)
- ZNTL 0.17
- PSTX 0.11
- MACD
- ZNTL 0.00
- PSTX -0.00
- Stochastic Oscillator
- ZNTL 38.33
- PSTX 32.14
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About PSTX Poseida Therapeutics Inc.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.